Fate Therapeutics Inc.

NASDAQ: FATE · Real-Time Price · USD
1.43
0.07 (5.15%)
At close: Jun 04, 2025, 3:59 PM
1.47
2.80%
After-hours: Jun 04, 2025, 07:54 PM EDT

Fate Therapeutics Statistics

Share Statistics

Fate Therapeutics has 114.63M shares outstanding. The number of shares has increased by 0.67% in one year.

Shares Outstanding 114.63M
Shares Change (YoY) 0.67%
Shares Change (QoQ) 0.62%
Owned by Institutions (%) 86.24%
Shares Floating n/a
Failed to Deliver (FTD) Shares 61,661
FTD / Avg. Volume 3.08%

Short Selling Information

The latest short interest is 12.87M, so 11.23% of the outstanding shares have been sold short.

Short Interest 12.87M
Short % of Shares Out 11.23%
Short % of Float 12.82%
Short Ratio (days to cover) 6.82

Valuation Ratios

The PE ratio is -1.01 and the forward PE ratio is -1.07. Fate Therapeutics's PEG ratio is 0.

PE Ratio -1.01
Forward PE -1.07
PS Ratio 13.76
Forward PS 4
PB Ratio 0.59
P/FCF Ratio -1.52
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Fate Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 7.58, with a Debt / Equity ratio of 0.27.

Current Ratio 7.58
Quick Ratio 7.58
Debt / Equity 0.27
Debt / EBITDA -0.48
Debt / FCF -0.69
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $75,309.39
Profits Per Employee $-1,029,071.82
Employee Count 181
Asset Turnover 0.03
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -62.84% in the last 52 weeks. The beta is 2.23, so Fate Therapeutics's price volatility has been higher than the market average.

Beta 2.23
52-Week Price Change -62.84%
50-Day Moving Average 1.08
200-Day Moving Average 2
Relative Strength Index (RSI) 60.55
Average Volume (20 Days) 1,999,246

Income Statement

In the last 12 months, Fate Therapeutics had revenue of 13.63M and earned -186.26M in profits. Earnings per share was -1.64.

Revenue 13.63M
Gross Profit 13.63M
Operating Income -210.28M
Net Income -186.26M
EBITDA -176.58M
EBIT -195.54M
Earnings Per Share (EPS) -1.64
Full Income Statement

Balance Sheet

The company has 36.06M in cash and 85.27M in debt, giving a net cash position of -49.21M.

Cash & Cash Equivalents 36.06M
Total Debt 85.27M
Net Cash -49.21M
Retained Earnings -1.4B
Total Assets 398.67M
Working Capital 220.06M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -122.87M and capital expenditures -730K, giving a free cash flow of -123.6M.

Operating Cash Flow -122.87M
Capital Expenditures -730K
Free Cash Flow -123.6M
FCF Per Share -1.09
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -1542.63% and -1366.46%.

Gross Margin 100%
Operating Margin -1542.63%
Pretax Margin -1366.46%
Profit Margin -1366.46%
EBITDA Margin -1295.41%
EBIT Margin -1542.63%
FCF Margin -906.79%

Dividends & Yields

FATE does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for FATE is $4, which is 194.1% higher than the current price. The consensus rating is "Hold".

Price Target $4
Price Target Difference 194.1%
Analyst Consensus Hold
Analyst Count 8
Stock Forecasts

Scores

Altman Z-Score -5.09
Piotroski F-Score 4